NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB
Post# of 48

Nutriband (NASDAQ: NTRB) has been granted U.S. patent No. 12,318,492 for its “Abuse and Misuse Deterrent Transdermal Systems,” further strengthening domestic protection for its Aversa(TM) technology. The patent, issued June 3, 2025, enhances the company’s intellectual property portfolio for abuse-deterrent transdermal products designed to curb misuse, diversion, and accidental exposure. Aversa(TM) is currently in development as part of Nutriband’s lead product, Aversa Fentanyl, which aims to be the first abuse-deterrent fentanyl patch on the market, with peak U.S. sales potential projected between $80 million and $200 million.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://nnw.fm/NTRB
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer

